HES1 and neoplasm: In summary, genetic knockdown of HES1 in FN‐RMS tumor xenografts showed inhibition of tumor growth with some induction of myogenic differentiation, supporting the therapeutic potential of targeting the HES1‐YAP1‐CDKN1C functional interaction in vivo.